

Freedom of Information Act 2000

The Royal Cornwall Hospitals NHS Trust Response to Information request

Date Request Received: 22<sup>nd</sup> July 2025

FOI Ref No 29645

Requested Information:

1. **Testing and Management Protocols for Carbapenem-Resistant Enterobacteriaceae (CRE)**
  - i. Does your trust have a clinical protocol for testing and managing patients for Carbapenem-Resistant Enterobacteriaceae (CRE)?  
**If yes:**
    - a. Is your CRE testing protocol primarily molecular-based?
    - b. If not, please specify which type of testing protocol is followed.
  - ii. Which diagnostic companies or providers does your trust procure molecular testing kits for services for CRE from?
2. **Testing Protocols for *Clostridioides difficile* (C. difficile) Infection**
  - i. Does your trust have a formal protocol for testing patients for *Clostridioides difficile* (C. difficile) infection?  
**If yes:**
    - a. Is your C. difficile testing protocol molecular-based?
    - b. If not, please specify the testing method used.
  - ii. Which diagnostic companies or providers does your trust procure molecular testing kits for services for C. difficile from?
3. **Testing and Procurement for Tuberculosis (TB) Resistance**
  - i. What methods does your trust use to test for tuberculosis (TB) resistance?
  - ii. Which diagnostic companies or providers does your trust procure molecular testing kits for services for TB resistance from?

Response:

1. **Yes, we do have a clinical protocol for testing and managing patients for CRE.**
  - a) **No, it is not molecular based – we use routine culture, Brilliance™ CRE agar**
2. **Yes, we have a formal protocol for testing patients with C.diff.**
  - a) **No, it is not molecular based. We use a combination of Biomeriuex VIDAS, C.diff and GDH along with Cepheid GeneXpert in some situations.**
3. **We refer are isolates away for TB resistance.**

**Attachment(s):**

No Attachment(s)

**Date Response sent: 23<sup>rd</sup> July 2025**